Floatz logo

Nivolumab

Lung Adenocarcinoma

Emory Universitymonoclonal_antibodyPhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
95/ 100

Competitive context

63 Active assets in the Lung Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Anusha Kalbasi
Phase 2BBB
Carboplatin
Guangdong Association of Clinical Trials
Phase 3BBB
Etoposide
Guangdong Association of Clinical Trials
Phase 3BB
Cis-Diamminedichloroplatinum Ii
Guangdong Association of Clinical Trials
Phase 3BB
Docetaxel
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3BB

View all 50 →

Same molecule, other indications

Nivolumab is also rated in:

renal carcinomaActive
BBB
Indicative · Phase 4
72 / 100
View asset →
metastatic melanomaActive
BB
Indicative · Phase 4
70 / 100
View asset →
non-small cell lung carcinomaActive
BB
Indicative · Phase 4
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →